Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet

Diab Vasc Dis Res. 2019 Jan;16(1):87-97. doi: 10.1177/1479164118795274. Epub 2018 Aug 29.

Abstract

An emerging body of evidence consistently suggests that compromised blood-brain barrier integrity may be causally associated with cognitive decline induced by type-2 diabetes. Our previous studies demonstrated that selected anti-inflammatory/anti-oxidative agents can preserve the integrity of blood-brain barrier and prevent neuroinflammation in mouse models of dysfunctional blood-brain barrier. Therefore, we have tested whether the previously proven blood-brain barrier protective agent, probucol, can prevent blood-brain barrier breakdown and cognitive decline in a dietary-induced murine model of diabetic insulin resistance. After 6-month chronic ingestion of a diet high in fat and fructose, the mice became insulin resistant. The high-fat and high-fructose-fed mice showed significant cognitive decline assessed by Morris water maze, concomitant with significant elevations in cortical and hippocampal glial acidic fibrillary protein and Fluoro Jade-C staining, indicating heightened neuroinflammation and neurodegeneration, respectively. The integrity of blood-brain barrier in high-fat and high-fructose-fed mice was substantially compromised, and this showed a significant association with heightened neurodegeneration. Co-provision of probucol with high-fat and high-fructose diet completely prevented the cognitive decline and blood-brain barrier dysfunction. Similarly, metformin was able to restore the cognitive function in high-fat and high-fructose-fed mice, while its blood-brain barrier protective effects were modest. These data suggest that probucol may prevent cognitive decline induced by insulin resistance by preserving the integrity of blood-brain barrier, whereas metformin's neuroprotective effects may be mediated through a separate pathway.

Keywords: Blood–brain barrier; Morris water maze; cognitive impairment; diabetes; high-fat and high-fructose diet; insulin resistance; metformin; neurodegeneration; neuroinflammation; probucol.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Behavior, Animal / drug effects*
  • Blood-Brain Barrier / drug effects*
  • Blood-Brain Barrier / metabolism
  • Blood-Brain Barrier / physiopathology
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / metabolism
  • Cerebral Cortex / physiopathology
  • Cognition / drug effects*
  • Cognition Disorders / blood
  • Cognition Disorders / physiopathology
  • Cognition Disorders / prevention & control*
  • Cognition Disorders / psychology
  • Cytokines / metabolism
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / physiopathology
  • Diabetes Mellitus, Experimental / psychology
  • Diet, High-Fat*
  • Fructose*
  • Glial Fibrillary Acidic Protein / metabolism
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Hippocampus / physiopathology
  • Hypoglycemic Agents / pharmacology
  • Inflammation Mediators / metabolism
  • Insulin Resistance
  • Male
  • Maze Learning / drug effects
  • Metformin / pharmacology
  • Mice, Inbred C57BL
  • Nerve Degeneration
  • Neuroprotective Agents / pharmacology*
  • Probucol / pharmacology*

Substances

  • Anti-Inflammatory Agents
  • Cytokines
  • Glial Fibrillary Acidic Protein
  • Hypoglycemic Agents
  • Inflammation Mediators
  • Neuroprotective Agents
  • glial fibrillary astrocytic protein, mouse
  • Fructose
  • Metformin
  • Probucol